



For personal use only



Rhythm Biosciences

An ASX Life Sciences Growth Opportunity

6 AUGUST 2026 – 20TH BIOSHARES BIOTECH SUMMIT

Disclaimer

This presentation has been prepared by **Rhythm Biosciences Limited** (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undertakings in this presentation.

This presentation is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. Rhythm makes no warranty or representation (express or implied) as to the accuracy, reliability or completeness of the information contained in this presentation. Specifically, several matters referred to in the presentation remain under investigation and are subject to change or even elimination, depending on further research and investigation. Further, any opinions (including any forward-looking statements) expressed in this presentation are subject to change without notice. Rhythm and its directors, officers, employees, advisers and agents shall have no liability (including liability to any person by reason of negligence or negligent misstatement) for any statements, opinions, information or matters (express or implied) arising out of, contained in or derived from or for any omissions from this presentation, except liability under statute that cannot be excluded.

This presentation, including the information contained in this disclaimer, does not form part of any offer, invitation or recommendation in respect of shares, or an offer, invitation or recommendation to sell, or a solicitation of any offer to buy, shares in the United States, or in any other jurisdiction in which, or to any person to whom, such an offer would be illegal.

This presentation may include forward-looking statements. Forward-looking statements are only predictions and are subject to known and unknown risks, uncertainties and assumptions, many of which are outside the control of Rhythm. Actual values, results or events may be materially different to those expressed or implied in this presentation depending on a range of factors. Given these uncertainties, recipients are cautioned not to place reliance on forward-looking statements. No representation or warranty (express or implied) is made by Rhythm or any of its directors, officers, employees, advisers or agents that any forecasts, projections, intentions, expectations or plans set out in this presentation will be achieved.

Cancer is often detected too late

Earlier detection significantly improves survival outcomes and lowers treatment costs.

15,500+

new colorectal cancer cases
diagnosed every year in Australia





>50%

diagnosed as late-stage
disease (Stages III or IV)




10%

5-year survival rate when
diagnosed at Stage IV



Detecting cancer earlier saves lives

Two complementary platforms. One longitudinal precision cancer diagnostic strategy.



RISK ASSESSMENT

Who is at risk?

Genomic cancer risk assessment that identifies elevated risk before symptoms emerge.

Assessing cancer risk before symptoms appear.

COLOSTAT®
Colorectal Cancer Test

DISEASE SCREENING

Who has the disease?

Blood-based bowel cancer detection that improves screening accessibility and compliance.

Non-invasive, blood-based bowel cancer detection.

Rhythm Biosciences sits at the intersection of precision medicine, preventative healthcare and scalable diagnostics – earlier detection, better outcomes, lower cost of care.

COLOSTAT®

Colorectal Cancer Test

A blood-based colorectal cancer detection platform designed to aid effective early diagnosis.

www.colostat.com

22 million patients waiting on a colonoscopy decision...

ColoSTAT®

OPPORTUNITY 1 OF 2

NEAR TERM



22M symptomatic patients could benefit from better-informed colonoscopy decisions. That's approximately 40% of annual colonoscopy volumes worldwide.



An alternative to stool-based testing

Many patients avoid stool-based testing delaying diagnosis



Prioritise patients at greatest risk

Help specialists identify which symptomatic patients should receive colonoscopy sooner.



Reduce unnecessary invasive procedures

Support alternative clinical management for patients less likely to benefit from colonoscopy.




Alleviate accessibility challenges

Regional and underserved communities face limited access to endoscopy facilities.

Estimated annual triage opportunity by region

Millions of potential tests per year: diagnostic colonoscopies



Global annual opportunity: 22.0m tests p.a.

ColoSTAT® is a simple blood test that tells the specialist who to scope first.

...and 290 million eligible people remain unscreened.

ColoSTAT®

OPPORTUNITY 2 OF 2

LONG TERM



~400 million

people are eligible for
bowel cancer screening

Estimated screening-age
population across target markets

~290 million

people do not participate in
recommended screening

Most eligible people remain outside
current screening pathways.

3 in 4

remain unscreened



Why?
Current screening
pathways leave major
participation gaps.

**Stool-based testing
limits participation**

Participation lifts from 38% to 69%
when patients are offered a choice of test.
Only ~56% follow up a positive result.

**Access to screening
remains unequal**

Geography, healthcare access, awareness
and cultural barriers can make screening
harder to reach and complete.

A blood-based option could expand participation and unlock a significant new screening market.

Scaling ColoSTAT[®] through established clinical channels

Clinically validated. Partner-enabled. Built for national scale.



AN ESTABLISHED MARKET

>800,000

colonoscopies performed annually in Australia

ColoSTAT[®] addresses patients who may not require immediate colonoscopy or who otherwise fall outside existing pathways.

A NATIONAL REFERRAL BASE

~41,000

primary care and specialist clinicians across Australia

Commercial reach through established referral pathways, supported by targeted clinician education and adoption.

EVIDENCE-LED ADOPTION

Clinical and economic evidence

Supports clinician confidence, routine use and the case for reimbursement.



Testing, analytics and commercial execution



National collection network and patient access

PARTNERSHIP-LED COMMERCIAL EXPANSION

Established infrastructure supports scalable national rollout of ColoSTAT[®].



**Personalised cancer risk assessment designed
to support earlier detection and prevention.**

www.genetype.com


Personalised cancer risk assessment at scale

geneType™

CANCER RISK ASSESSMENT PLATFORM



How geneType™ reaches the market



- Clinics – 25%
Direct volume. Health Care Professionals (B2B). Clinics provide an immediate route to patients and support early test uptake.
- Enterprise – 75%
Enterprise accounts & strategic partners (B2B2C). Health, insurance and other enterprise partners can extend access across larger populations.

Projected test volume mix across the forecast period, with most volume expected to come through enterprise accounts and strategic partners.

A broader cancer portfolio

Six[#] cancer risk assessments, including three that complement Rhythm's protein biomarker programs.



Breast*



Prostate



Colorectal*



Ovarian



Pancreatic*



Melanoma

* Rhythm Biosciences protein biomarker program overlap.

Colorectal cancer test pending transfer to production

A single platform covering six cancers, delivered through clinics and enterprise partners.

Rhythm Biosciences at a glance

Building a scalable precision diagnostics platform



CORPORATE SNAPSHOT

5 JUNE 2026

ASX Code

RHY

Share Price

\$0.086

Shares on Issue

353.9M

Unlisted & Listed Options

71.8M

Market Capitalisation

\$27.4M

Cash in Bank (30 June 2026)

\$3.354M

Top 20 Shareholders

41.6%



RISK ASSESSMENT

Personalised cancer risk assessment designed to support earlier detection and prevention.

www.genetype.com

COLOSTAT®
Colorectal Cancer Test

ACCESSIBLE DETECTION

A blood-based colorectal cancer detection platform designed to improve accessibility, compliance and earlier diagnosis.

www.colostat.com

FY27 Catalysts

Positioned for the next phase of commercial expansion and international growth.



For personal use only

PRODUCT	ITEM	DESCRIPTION	COMPLETION DATE
ColoSTAT®	Scaling commercial footprint	Activation of additional 4Cyte collection centres	Q1 FY27
geneType™	geneType™ strategic partnerships	Establishment of key international and domestic commercial partners	Q1 FY27
ColoSTAT®	ColoSTAT® Access Program	Complete physician enrolment for the ColoSTAT® Access Program (20 participating physicians)	Q1 FY27
ColoSTAT®	ColoSTAT® Economics	Complete ColoSTAT® economic analysis	Q1 FY27
geneType™	geneType™ Reimbursement	Complete the development of a reimbursement strategy for the US market	Q2 FY27
ColoSTAT®	International expansion: UK	Completion of first phase of NHS ColoSTAT® evaluation	Q2 FY27
ColoSTAT®	ColoSTAT® Reimbursement	Complete MSAC Submission	Q3 FY27
ColoSTAT®	Real World Evidence	Interim analysis of data collected in the ColoSTAT® Access Program designed to evaluate ColoSTAT® in the real-world setting	Q3 FY27

Team

Experienced diagnostics leadership executing the next phase of commercial growth



David Atkins, PhD
CEO & MD

Former CEO of Congenica (UK) & Synevo Diagnostics, Sr. Executive at Johnson & Johnson and Danaher.

Founder of Veridex – cancer molecular and cellular diagnostics (USA).

Experience in product development and commercial leadership in the global medical device and diagnostic industry. Also an active member of BioNSW and InGeNA.



Sue MacLeman
Non-Executive Director

30 years in Pharma, Biotech and Medtech including Amgen, BMS and Merck and SME's.

Experienced Board member, former CEO of NASDAQ, ASX, & AIM entities. Currently Chair of Medicines Australia, NED & Chair at Viral Vector Manufacturing Facility, Smartways Logistics, Healthcare Translation Group, OMICO & member of the National Research Infrastructure (NRI) Advisory Group.



Gavin Fox-Smith
Non-Executive Director

38 years as a leader and champion of Medical Technology in Australia/NZ and Asia.

Gavin is Chair of ANDHealth (Australia's National Digital Health Initiative), Board Director for Bowel Cancer Australia and Board Director for SAN Foundation.

Gavin was previously CEO of Omnigon, a private Australian company in the Ostomy Care market.



Jackson Jones
Chief Commercial Officer



Gary Goh
Head of Laboratory
Operations and RA/QA



Erika Spaeth
Director of geneType
Clinical & Scientific Affairs



Andy Feber
Director of Diagnostic
Clinical & Scientific Affairs

Why Rhythm Biosciences? Why now?



Dual-platform precision diagnostics strategy

Longitudinal disease management: Combining personalised risk assessment and earlier cancer detection.



Commercialisation underway

Development risks largely retired. Commercial validation, partnerships and rollout progressing across several markets.



Large global addressable markets

Exposure to significant and growing global cancer diagnostics demand.



Thank you!

David Atkins, PhD

david.atkins@rhythmbio.com

www.rhythmbio.com